Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

States redesigning mental health programs, coverage and care

States are grappling with mental health issues including a redesign of a program in Iowa, increased coverage for the mentally ill in California and a mental health first aid pilot program in Pennsylvania.

30 Jan 2012

Potential role of omega-3 fatty acid in preventing psychological consequences of accidents

A report in the 5th 2011 issue of Psychotherapy and Psychosomatics suggests the potential role of omega-3 fatty acid in preventing the psychological consequences of an accident.

23 Jan 2012

Study aims to help adult men and women with SAD

If winter's long nights and cold weather have you feeling depressed, a new research study could lift your spirits. The study, lead by Janis Anderson, PH.D., an associate psychologist in the Brigham and Women's Hospital Department of Psychiatry, aims to help adult (ages 21-64) men and women with Seasonal Affective Disorder (SAD) by comparing two new types of light technologies to determine which one works better.

20 Jan 2012

Successful integration of care of technology-dependent child into family life helps families function better

Normal everyday life for parents requires organization. Parents of children who require ventilators, oxygen, IVs and other tools to live, those day-to-day tasks can be time-consuming, difficult and stressful on the family.

6 Jan 2012

Low levels of vitamin D may increase risk of depression

Low levels of vitamin D have been linked to depression, according to UT Southwestern Medical Center psychiatrists working with the Cooper Center Longitudinal Study. It is believed to be the largest such investigation ever undertaken.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

RNF123 gene may play a role in major depression

Psychiatric disorders can be described on many levels, the most traditional of which are subjective descriptions of the experience of being depressed and the use of rating scales that quantify depressive symptoms. Over the past two decades, research has developed other strategies for describing the biological underpinnings of depression, including volumetric brain measurements using magnetic resonance imaging (MRI) and the patterns of gene expression in white blood cells.

4 Jan 2012

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

A new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder (MDD) or bipolar ll disorder.

3 Jan 2012

Celiac disease may increase risk of disordered eating, depression in women

Women with celiac disease -- an autoimmune disorder associated with a negative reaction to eating gluten -- are more likely than the general population to report symptoms of depression and disordered eating, even when they adhere to a gluten-free diet, according to researchers at Penn State, Syracuse University and Drexel University.

28 Dec 2011

People with congenital facial disfigurement have 'relatively normal' psychological functioning

People born with severe facial disfigurement have generally good psychological adjustment in adulthood, according to a study in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

22 Dec 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 study on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the second of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

20 Dec 2011

First reliable method to predict whether SSRIs work on depressed patients

Loyola University Medical Center researchers are reporting what could become the first reliable method to predict whether an antidepressant will work on a depressed patient.

16 Dec 2011

Individuals with mood and anxiety disorders may be more likely to abuse opioids

Individuals suffering from mood and anxiety disorders such as bipolar, panic disorder and major depressive disorder may be more likely to abuse opioids, according to a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health. They found that mood and anxiety disorders are highly associated with non-medical prescription opioid use.

14 Dec 2011

Individuals with mood disorders twice as likely to have heart attacks

Depression may have more far-reaching consequences than previously believed. Recent data suggests that individuals who suffer from a mood disorder could be twice as likely to have a heart attack compared to individuals who are not depressed.

29 Nov 2011

Migraines and depression risk: Study finds link

According to a new Canadian study, people who get attacks of migraine may be at a higher risk for developing clinical depression.

27 Nov 2011

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005.

18 Nov 2011

Higher protein load in critical brain regions linked to severe depression in late life

Depression is one of the most common mental disorders in the elderly, but little is known about the underlying biology of its development in older adults.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011